{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:39:58Z","timestamp":1792755598299,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"DOI":"10.1038\/s41591-026-04711-0","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:01:33Z","timestamp":1792753293000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bispecific dual T cell agonist invikafusp alfa in solid tumors: the phase 1\/2 START-001 trial"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5344-6645","authenticated-orcid":false,"given":"Ryan J.","family":"Sullivan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2389-9974","authenticated-orcid":false,"given":"Nicholas P.","family":"Tschernia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire F.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8553-3919","authenticated-orcid":false,"given":"Mercedes","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1010-9611","authenticated-orcid":false,"given":"Guru P.","family":"Sonpavde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4378-9297","authenticated-orcid":false,"given":"Kai","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8540-5351","authenticated-orcid":false,"given":"Antoine","family":"Italiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5816-3019","authenticated-orcid":false,"given":"Aur\u00e9lien","family":"Marabelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3192-2342","authenticated-orcid":false,"given":"Matthieu","family":"Roulleaux-Dugage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois-Xavier","family":"Danlos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4412-7842","authenticated-orcid":false,"given":"Elena Garralda","family":"Cabanas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Hernando-Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9760-9470","authenticated-orcid":false,"given":"Manuel","family":"Pedregal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5245-7841","authenticated-orcid":false,"given":"Aparna","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5093-6099","authenticated-orcid":false,"given":"Gopakumar","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Zakari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0477-1956","authenticated-orcid":false,"given":"E. John","family":"Wherry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7932-4072","authenticated-orcid":false,"given":"Jeffrey","family":"Schlom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6828-3073","authenticated-orcid":false,"given":"Renee N.","family":"Donahue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0950-5352","authenticated-orcid":false,"given":"Shannon","family":"McCue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karunya","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Benincosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madan","family":"Katragadda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenming","family":"Shun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8391-3566","authenticated-orcid":false,"given":"Ke","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3500-0540","authenticated-orcid":false,"given":"Lillian L.","family":"Siu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6569-2912","authenticated-orcid":false,"given":"James L.","family":"Gulley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"key":"4711_CR1","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMsb2300232","volume":"388","author":"PC Johnson","year":"2023","unstructured":"Johnson, P. C., Gainor, J. F., Sullivan, R. J., Longo, D. L. & Chabner, B. Immune checkpoint inhibitors\u2014the need for innovation. N. Engl. J. Med. 388, 1529\u20131532 (2023).","journal-title":"N. Engl. J. Med."},{"key":"4711_CR2","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","volume":"37","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld, A. J. & Hellmann, M. D. Acquired resistance to immune checkpoint inhibitors. Cancer Cell 37, 443\u2013455 (2020).","journal-title":"Cancer Cell"},{"key":"4711_CR3","doi-asserted-by":"publisher","first-page":"2308097","DOI":"10.1080\/15384047.2024.2308097","volume":"25","author":"GS Santiago-S\u00e1nchez","year":"2024","unstructured":"Santiago-S\u00e1nchez, G. S., Fabian, K. P. & Hodge, J. W. A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance. Cancer Biol. Ther. 25, 2308097 (2024).","journal-title":"Cancer Biol. Ther."},{"key":"4711_CR4","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s40259-024-00700-2","volume":"39","author":"A Mariniello","year":"2025","unstructured":"Mariniello, A. et al. Primary and acquired resistance to immunotherapy with checkpoint inhibitors in NSCLC: from bedside to bench and back. BioDrugs 39, 215\u2013235 (2025).","journal-title":"BioDrugs"},{"key":"4711_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2019.12.010","volume":"13","author":"L Barrueto","year":"2020","unstructured":"Barrueto, L. et al. Resistance to checkpoint inhibition in cancer immunotherapy. Transl. Oncol. 13, 100738 (2020).","journal-title":"Transl. Oncol."},{"key":"4711_CR6","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/00000658-199809000-00004","volume":"228","author":"SA Rosenberg","year":"1998","unstructured":"Rosenberg, S. A., Yang, J. C., White, D. E. & Steinberg, S. M. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann. Surg. 228, 307\u2013319 (1998).","journal-title":"Ann. Surg."},{"key":"4711_CR7","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1007\/s00262-016-1910-x","volume":"65","author":"A Alva","year":"2016","unstructured":"Alva, A. et al. Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Cancer Immunol. 65, 1533\u20131544 (2016).","journal-title":"Cancer Immunol."},{"key":"4711_CR8","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","volume":"18","author":"RS Riley","year":"2019","unstructured":"Riley, R. S., June, C. H., Langer, R. & Mitchell, M. J. Delivery technologies for cancer immunotherapy. Nat. Rev. Drug Discov. 18, 175\u2013196 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"4711_CR9","doi-asserted-by":"publisher","first-page":"1847986","DOI":"10.3389\/fimmu.2026.1847986","volume":"17","author":"Q Yang","year":"2026","unstructured":"Yang, Q., Wang, S., Liu, F., Yu, Y. & Zhao, H. The trinity of T cell engagement: navigating the molecular and clinical landscape of CAR-T, TILs, and TCEs in the war against cancer. Front. Immunol. 17, 1847986 (2026).","journal-title":"Front. Immunol."},{"key":"4711_CR10","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adj6174","volume":"9","author":"P Vantourout","year":"2023","unstructured":"Vantourout, P. et al. Innate TCR\u03b2-chain engagement drives human T cells toward distinct memory-like effector phenotypes with immunotherapeutic potentials. Sci. Adv. 9, eadj6174 (2023).","journal-title":"Sci. Adv."},{"key":"4711_CR11","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adi0258","volume":"15","author":"J Hsu","year":"2023","unstructured":"Hsu, J. et al. A T cell receptor \u03b2 chain-directed antibody fusion molecule activates and expands subsets of T cells to promote antitumor activity. Sci. Transl. Med. 15, eadi0258 (2023).","journal-title":"Sci. Transl. Med."},{"key":"4711_CR12","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/ng.3581","volume":"48","author":"B Li","year":"2016","unstructured":"Li, B. et al. Landscape of tumor-infiltrating T cell repertoire of human cancers. Nat. Genet. 48, 725\u2013732 (2016).","journal-title":"Nat. Genet."},{"key":"4711_CR13","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1158\/1078-0432.CCR-20-3725","volume":"27","author":"P Deegen","year":"2021","unstructured":"Deegen, P. et al. The PSMA-targeting half-life extended BiTE therapy AMG 160 has potent antitumor activity in preclinical models of metastatic castration-resistant prostate cancer. Clin. Cancer Res. 27, 2928\u20132937 (2021).","journal-title":"Clin. Cancer Res."},{"key":"4711_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.102625","volume":"52","author":"PJ Engelberts","year":"2020","unstructured":"Engelberts, P. J. et al. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine 52, 102625 (2020).","journal-title":"EBioMedicine"},{"key":"4711_CR15","doi-asserted-by":"publisher","first-page":"e70069","DOI":"10.1002\/cncr.70069","volume":"131","author":"D Synnott","year":"2025","unstructured":"Synnott, D., O\u2019Reilly, D., De Freitas, D. & Naidoo, J. Cytokine release syndrome in solid tumors. Cancer 131, e70069 (2025).","journal-title":"Cancer"},{"key":"4711_CR16","doi-asserted-by":"publisher","first-page":"856961","DOI":"10.3389\/fphar.2022.856961","volume":"13","author":"T Dunlap","year":"2022","unstructured":"Dunlap, T. & Cao, Y. Physiological considerations for modeling in vivo antibody-target interactions. Front. Pharmacol. 13, 856961 (2022).","journal-title":"Front. Pharmacol."},{"key":"4711_CR17","doi-asserted-by":"publisher","first-page":"e83659","DOI":"10.7554\/eLife.83659","volume":"12","author":"C Liu","year":"2023","unstructured":"Liu, C. et al. Population dynamics of immunological synapse formation induced by bispecific T cell engagers predict clinical pharmacodynamics and treatment resistance. eLife 12, e83659 (2023).","journal-title":"eLife"},{"key":"4711_CR18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/psp4.12369","volume":"8","author":"J Schropp","year":"2019","unstructured":"Schropp, J., Khot, A., Shah, D. K. & Koch, G. Target-mediated drug disposition model for bispecific antibodies: properties, approximation, and optimal dosing strategy. CPT Pharmacometrics Syst. Pharmacol. 8, 177\u2013187 (2019).","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"4711_CR19","unstructured":"Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases: Guidance for Industry; Availability https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/optimizing-dosage-human-prescription-drugs-and-biological-products-treatment-oncologic-diseases (US Food & Drug Administration, 2024)."},{"key":"4711_CR20","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.1016\/j.annonc.2025.05.496","volume":"36","author":"EE Fernandez","year":"2025","unstructured":"Fernandez, E. E. et al. Phase I\/II clinical investigation of invikafusp alfa, a first-in-class TCR-beta chain-targeted bispecific antibody, as monotherapy in patients with anti-PD(L)1-resistant, antigen-rich gastrointestinal (GI) cancers. Ann. Oncol. 36, S181 (2025).","journal-title":"Ann. Oncol."},{"key":"4711_CR21","doi-asserted-by":"publisher","first-page":"PS5-09-16","DOI":"10.1158\/1557-3265.SABCS25-PS5-09-16","volume":"32","author":"S Isakoff","year":"2026","unstructured":"Isakoff, S. et al. A phase 1b\/2 clinical investigation of invikafusp alfa (STAR0602), a first-in-class dual T-cell agonist, in combination with sacituzumab govitecan in patients with metastatic TNBC or HR+\/HER2- MBC (START-002 trial). Clin. Cancer Res. 32, PS5-09-16 (2026).","journal-title":"Clin. Cancer Res."},{"key":"4711_CR22","doi-asserted-by":"publisher","first-page":"e007309","DOI":"10.1136\/jitc-2023-007309","volume":"11","author":"H Tawbi","year":"2023","unstructured":"Tawbi, H. et al. Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development. J. Immunother. Cancer 11, e007309 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"4711_CR23","doi-asserted-by":"publisher","first-page":"e004601","DOI":"10.1136\/jitc-2022-004601","volume":"10","author":"YT Tsai","year":"2022","unstructured":"Tsai, Y. T. et al. Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa. J. Immunother. Cancer 10, e004601 (2022).","journal-title":"J. Immunother. Cancer"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04711-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04711-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04711-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:01:35Z","timestamp":1792753295000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04711-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":23,"alternative-id":["4711"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04711-0","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"21 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.J.S. has received research funding (to institution) from BioNTech SE, Bristol Myers Squibb, Genentech\/Roche, Georgiamune, Immunocore, Marengo Therapeutics, Merck, Moderna, Novartis, Pfizer, Relay, Springworks and Synthekine and has been a consultant\/advisory board member for Marengo Therapeutics, Merck, Novartis, Pfizer, PharmaMar and Replimune. N.P.T., R.N.D., J.S. and J.L.G. work for NCI, NIH, which has a Cooperative Research and Development Agreement (CRADA) with Marengo Therapeutics. This CRADA provides resources for co-development of invikafusp alfa. These NIH authors do not have any competing interests to disclose. C.F.F. is an employee of Lilly and receives institutional funding to Memorial Sloan Kettering Cancer Center. M.H., M.P. and M.R.-D. have nothing to disclose. G.P.S. is on the advisory board for EMD Serono, Bristol Myers Squibb, Merck, Seattle Genetics, Astellas, Janssen, Bicycle Therapeutics, Pfizer, Gilead, Lilly, Loxo Oncology, Aktis, Daiichi Sankyo, GlaxoSmithKline and Abbott; serves as a consultant or member of the scientific advisory board\/trial steering committee for Merck, Ellipses, Lucence and Coiled Therapeutics; receives research support (to institution) from EMD Serono, Jazz Pharmaceuticals, Bayer, Sumitomo Pharma and Blue Earth Diagnostics; is a speaker for Seagen, Gilead, Natera, Exelixis, Janssen, Astellas, Bayer, Aveo, Pfizer, Merck and AstraZeneca; and has received travel support from Bristol Myers Squibb, Astellas and Merck. G.P.S.\u02bcs spouse is employed by Myriad, Exact Sciences and Abbott. K.H. (current affiliation: The University of Texas at San Antonio Mays Cancer Center) has received research funding (to institution) from A2bio, AbbVie, Adaptimmune, Amgen, BioNTech SE, Bristol Myers Squibb, Genentech\/Roche, GlaxoSmithKline, Iovance Biotherapeutics, Marengo Therapeutics, Mirati Therapeutics, Obsidian Therapeutics, OncoC4, Servier and Synthekine and is a consultant for Amgen, AstraZeneca, BioNTech SE, Bristol Myers Squibb, Iovance Biotherapeutics, Lyell Immunopharma, Mirati Therapeutics, Perthera, Pfizer, Obsidian Therapeutics, Lilly, OncoC4 and Synthekine. A.I. receives research support (to institution) from AstraZeneca, Bayer, Bristol Myers Squibb, F. Hoffmann-La Roche and Merck and consultant fees (personal) from Chugai Pharmaceutical. A.M. has received travel funding from Bristol Myers Squibb, Roche\/Genentech, Incyte and MSD; has acted in a consulting or advisory role for Adagene, AstraZeneca, BioLineRx, Centessa Pharmaceuticals, Clover Biopharmaceuticals, Deka Biosciences, Depth Charge Therapeutics, Eisai, Greywolf Therapeutics, Gritstone Bio, Guidepoint Global, HiFiBiO Therapeutics, Hotspot Therapeutics, Innate Pharma, lmCheck Therapeutics, Johnson & Johnson\/Janssen, Lytix Biopharma, Medicxi, MSD, Neogene Therapeutics, OSE Immunotherapeutics, PegaOne, Pierre Fabre, Roche, Redx Pharma, Sanofi, Servier, Shattuck Labs, Sotio and Third Rock Ventures; and has stock or ownership in Centessa Pharmaceuticals, Deka Biosciences, HotSpot Therapeutics, Marengo Therapeutics and Shattuck Labs. F.-X.D. holds a consulting or advisory role for Merck KGaA. E.G.C. has received funding (to institution) from Novartis, Roche, Thermo Fisher Scientific, AstraZeneca, Taiho, BeiGene Medicines, Janssen and Anaveon; consulting fees from Roche, Ellipses Pharma, Boehringer Ingelheim, Janssen Global Services, Seattle Genetics, Skypta, Sotio, Sanofi, AbbVie, Astex Therapeutics, Alentis Therapeutics, Marengo Therapeutics, Incyte, Lilly, Medpace, Pfizer, Amgen, GenMab, Genentech, Greywolf Therapeutics, Gilead, Daiichi Sankyo, Takeda Pharmaceuticals, Pyramid Biosciences, Epics Therapeutics, Ayuvant Biotech, Apmonia Therapeutics and Cancer Research Horizons; and honoraria for speaking bureaus from Roche, Ellipses Pharma, Boehringer Ingelheim, Janssen Global Services, Seattle Genetics, Skypta, Sotio, Sanofi, Anaveon, AbbVie, Astex Therapeutics, Alentis Therapeutics, Marengo Therapeutics, Incyte, Lilly, Medpace, Pfizer, Amgen, GenMab, Genentech, Greywolf Therapeutics, Gilead, Daiichi Sankyo, Takeda Pharmaceuticals, Pyramid Biosciences, Epics Therapeutics, Ayuvant Biotech, Apmonia Therapeutics and Cancer Research Horizons. She is an employee of NEXT Oncology and holds stock in 1TRIALSP. A.H.-C. reports advisory council or committee membership from Boehringer Ingelheim, Karger Publishers and Slingshot Insights; honoraria from CDDF and Fundaci\u00f3n SEOM; and grants or funds (to institution) from Bayer, Bicara Therapeutics, Boehringer Ingelheim, CDR-life, Gilead, GlaxoSmithKline, NEC Bio, Novartis and Vividion Therapeutics (all institution). A.P. receives consulting fees (personal) from Pfizer, Roche (Data and Safety Monitoring Committee), Biofidelity, Bristol Myers Squibb, Checkmate Pharmaceuticals, CVS Caremark Corporation, Lilly, Zola and Inivata and fees paid to institution from Novartis, PMV Pharmaceuticals, PureTech Health, Daiichi Sankyo, Genentech and Mirati Therapeutics. G.I. reports institutional research funding from AADi, Flare Therapeutics, Janssen, Loxo Oncology\/Lilly and Pfizer and personal\/consulting or advisory fees from AstraZeneca, Bicycle Therapeutics, Daiichi Sankyo, EMD Serono, Flare Therapeutics, Janssen Research and Development, Loxo Oncology\/Lilly, Mirati Therapeutics and Pfizer, outside the submitted work. A.Z. is on the speaker program for Inocyte, BeOne Medicines, Exelixis, AstraZeneca and Geron. E.J.W. is an advisor for Arpelos Bio, Arsenal Biosciences, Coherus, Danger Bio, IpiNovyx, New Limit, Marengo Therapeutics, Pluto Immunotherapeutics, Related Sciences, Santa AnaBio and Synthekine; is a founder of Arpelos Bio, Arsenal Biosciences and Danger Bio; and holds stock in Coherus. S.M., S.C., K.S., L.B,. M.K., Z. Shun, K.C., Z. Su and K.L. are employees of Marengo Therapeutics. L.L.S. is a consultant\/advisory board member for Merck, Roche, Voronoi, GlaxoSmithKline, Bayer, Pfizer, Arvinas, Daiichi Sankyo, Amgen, Pangea, Tubulis, LTZ Therapeutics, Marengo Therapeutics, AstraZeneca, Incyte, Gilead, Bristol Myers Squibb, Systinn, Systimmune, EMD Serono and MBrace. Her institution receives grant\/research (clinical trials) support from Bristol Myers Squibb, Roche\/Genentech, GlaxoSmithKline, Merck, Novartis, Pfizer, AstraZeneca, Boehringer Ingelheim, Bayer, Amgen, AbbVie, EMD Serono, Daiichi Sankyo, Gilead, Marengo Therapeutics, Incyte, Legochem, Lilly and Daiichi Sankyo. She has stock ownership in Marengo Therapeutics and MBrace. Her spouse is a co-founder of Treadwell Therapeutics. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}